Equity Overview
Price & Market Data
Price: $4.00
Daily Change: +$0.01 / 0.25%
Range: $3.90 - $4.39
Market Cap: $203,910,400
Volume: 71,371
Performance Metrics
1 Week: 1.01%
1 Month: -18.86%
3 Months: -45.13%
6 Months: -59.31%
1 Year: -72.97%
YTD: -39.85%
Company Details
Employees: 57
Sector: Health technology
Industry: Biotechnology
Country: Canada
Details
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.